Adele is a globally recognized healthcare executive, known for industry-leading clinical development and commercialization of the world’s most successful medicines at Pfizer, AstraZeneca, Viatris and Sumitomo Pharma.

She most recently served as Chief Executive Officer, Biopharma Commercial Unit, for Sumitomo Pharma America, Inc. [TSE:4506] where she led the organization to 46% revenue growth and delivered significant profit improvement across a diverse portfolio spanning oncology, rare disease, urology, neurology and women’s health.
Ms. Gulfo previously served as Country Manager for Pfizer’s U.S. biopharmaceutical businesses, including Specialty, Oncology, and Vaccines, which generated over $20B during her tenure. She also served as President of Latin America, leading a $4B business with more than 4,000 colleagues across 24 countries, and as President and General Manager of Pfizer’s $12B+ U.S. primary care business unit, managing 5,000+ employees across multiple therapeutic areas. She later served as Executive Vice President, Chief Strategy Officer, and Head of Global Commercial Development at Mylan (now Viatris).

Prior to her time at Pfizer, Ms. Gulfo spent nine years at AstraZeneca where she held executive P&L roles in General Management and Business Development. She led the company’s Cardiovascular business unit spearheading the successful launch of CRESTOR® (peak sales $6.6B) and securing a transformative diabetes partnership with BMS. Earlier in her career, Ms. Gulfo planned and executed the commercial launch for LIPITOR®, the world’s most successful branded medicine, which achieved peak U.S. sales exceeding $13B.

Ms. Gulfo has extensive public company board experience, having served on various committees, including Audit, Nominating and Governance, Compensation, and Investment. She currently serves on Enpro [NYSE:NPO], a leading industrial engineering firm that designs, develops, and manufactures proprietary engineered products for use in semiconductor, nuclear, pharma, and aerospace. She also serves on the boards of New Amsterdam Pharma [NASDAQ: NAMS], which focuses on cardiovascular disease and Tyra Biosciences [NASDAQ: TYRA], which specializes in oncology and rare disease. Previously, she served on Myovant [NYSE: MYOV], which was acquired by Sumitomo Pharma. She also served on the board of Bemis Company [NYSE: BMS] a global supplier of industrial and healthcare packaging until its acquisition by Amcor [NYSE: AMCR]. She served on Medexus [TSX:MDP] a Biopharma company with a portfolio across allergy, dermatology, hematology and rheumatology. She currently serves on the Innovation Growth Board for Mass General Brigham, the largest U.S. hospital-based research enterprise in with $2B+ in annual funding.

Trained as a scientist, Ms. Gulfo has six U.S. patents. She earned a Bachelor of Science degree in Biology from Seton Hall University, an MBA with highest honors from Fairleigh Dickinson University, pursued post-graduate studies in Molecular Biology and began her career at the Rutgers School of Biomedical Sciences.